Sermorelin Evidence Guide
Sermorelin has FDA-approved history (pediatric GHD) and Phase 2 human data on GH stimulation and body composition, though its short half-life limits practical utility compared to longer-acting GHRH analogs. Evidence is weaker than tesamorelin but stronger than most other GHRH analogs. For GHRH-pathway research, tesamorelin or CJC-1295 are better-evidenced alternatives depending on the endpoint.
Our Take
Sermorelin has FDA-approved history (pediatric GHD) and Phase 2 human data on GH stimulation and body composition, though its short half-life limits practical utility compared to longer-acting GHRH analogs. Evidence is weaker than tesamorelin but stronger than most other GHRH analogs. For GHRH-pathway research, tesamorelin or CJC-1295 are better-evidenced alternatives depending on the endpoint.
- Best for
- GH deficiency investigation, GHRH axis research, anti-aging GH stimulation
- Evidence grade
- Level B
- Confidence
- Moderate
- Starting point
- 200-300mcg subcutaneous, nightly
Benefits and Evidence
- Growth Hormone Stimulation: Level B, includes human evidence - Well-documented ability to stimulate GH release in both children and adults. Less potent than exogenous GH but produces more physiological GH patterns.
- Body Composition (Adults): Level C, includes human evidence - Limited evidence for improved lean body mass and reduced body fat in GH-deficient adults. Effects are gradual and modest compared to direct GH therapy.
- Sleep Quality: Level C, includes human evidence - Some evidence of improved sleep quality, particularly deep sleep stages, consistent with the role of GH in sleep regulation.
Side Effects and Warnings
- Injection site reactions (redness, swelling)
- Facial flushing
- Headache
- Dizziness
- Sleepiness
- Previously FDA-approved but discontinued (for commercial, not safety reasons)
- May not be effective in severe pituitary damage
- Monitor for excessive GH/IGF-1 elevation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 100-300 mcg - Once daily at bedtime - Bedtime dosing optimizes natural nocturnal GH pulse. Take on empty stomach.
- <strong>Subcutaneous (combined)</strong> - 100-200 mcg - Once or twice daily - Often combined with ipamorelin or GHRP-6 for synergistic effects.
Mechanism of Action
Sermorelin stimulates GH through the natural GHRH pathway: 1. GHRH receptor activation: Directly binds pituitary GHRH receptors to stimulate GH synthesis and secretion. 2. Physiological GH release: Promotes natural pulsatile GH release pattern, unlike exogenous GH which creates non-physiological levels. 3. Negative feedback preserved: Does not override the body's negative feedback mechanisms, reducing risk of supraphysiological GH levels. 4. Pituitary health: May support pituitary somatotroph health and function long-term. 5. IGF-1 normalization: Gradually normalizes IGF-1 levels through sustained physiological GH stimulation.
Legal Status
Previously FDA-approved (Geref, 1997), discontinued by manufacturer in 2008. Still available through compounding pharmacies by prescription. Not a controlled substance. FDA placed restrictions on compounding in 2023 but later reversed some decisions.
Primary Sources
- Sermorelin: a review of its use in the diagnosis and treatment of growth hormone deficiency. Drugs, 2006.
- Effects of 6-month administration of sermorelin on body composition in elderly subjects. J Clin Endocrinol Metab, 1997.